DIAGONAL BIO AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0752 SEK | -5.41% |
|
-13.96% | -78.70% |
| Apr. 05 | Diagonal Bio AB Announces the Extension of Its Partnership with Horsholm Veterinary Clinic | CI |
| Apr. 05 | Diagonal Bio AB Announces Successful Pilot Study Results | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Diagonal Bio AB is a Sweden-based medical research company. The Company is developing a diagnostic platform (Panviral) for detection of any kind of pathogen. Panviralâs technology is based on rapid isothermal amplification of a pathogenâs genome. Multiple tests can be run in parallel, thereby increasing the sample throughput.
Calendar
2024-05-30
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -78.70% | 2.75M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DIABIO Stock
- News Diagonal Bio AB
- Diagonal Bio Makes Interim CEO Permanent
